Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Sarcomatoid renal cell cancer is associated with a very poor prognosis, characterized by rapid progression of advanced disease. We previously reported the outcome of 18 patients with advanced sarcomatoid renal cell cancer treated with a regimen consisting of doxorubicin, 50 mg/m2 and gemcitabine, 1,500–2,000 mg/m2, administered every two weeks with growth factor support (A/G). Among the 18 patients, there were two complete and 5 partial responses and two patients with stable disease of more than 6 months of duration. We now report long-term survival of 4 patients with stage IV sarcomatoid renal cell carcinoma treated with this regimen at the 1,500 mg/m2 dose of gemcitabine, and achieving complete response (2 patients), or rendered complete responders following surgery after maximum response (2 patients). The two complete responders are alive, disease free at 6+ and 8+ years after starting A/G, and the 2 patients rendered CR by surgery survived 3½ and 6 years, respectively. Both died of progressive disease, one with clear cell recurrence, one with sarcomatoid recurrence. In summary, this regimen is associated with a high response rate, overall improvement in progression free survival and occasional meaningful long-term survival in a disease expected to be fatal within one year.
- Wu JJ, Caliendo G, Hu X-P, Dutcher JP. Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma. Med Oncol. 1998;15:44–9. CrossRef
- Mian BM, Bhadkamkar N, Slaton JW, et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol. 2002;167:65–70. CrossRef
- Tsui KH, Shvarts O, Smith RB, Figline RA, deKernion JB, Belldegrun A. Prgnostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163:1090–4. PMID: 10737472. CrossRef
- Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26:281–91. CrossRef
- Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612–24. CrossRef
- Patard JJ, Leray E, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23:2763–71. CrossRef
- Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004;28:435–41. CrossRef
- de Peralt-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001;25:275–84. CrossRef
- Bangalore N, Bhargava P, Hawkins MJ, et al. Sustained response of sarcomatoid renal cell carcinoma to MAID chemotherapy. Case report and review of the literature. Ann Oncol. 2001;12:271–4. CrossRef
- Hoshi S, Satoh M, Ohyama C, Hiramatu M, et al. Active chemotherapy for bone metastases in sarcomatoid renal cell carcinoma. Int J Clin Oncol. 2003;8:113–7. CrossRef
- Sella A, Logothetis CJ, Ro JY, et al. Sarcomatoid renal cell carcionoma: a treatable entity. Cancer. 1987;60:1313–8. CrossRef
- Escudier B, Droz JP, Rolland F, et al. Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol. 2002;168:959–61. CrossRef
- Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer. 2004;101:1545–51. CrossRef
- Haas N, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wildiing G, Dutcher JP : ECOG 8802: a phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features. Proc GU ASCO. 2009.
- Rini BI, Vogelzang NJ, Dumas MC, Wade JL III, Taber DA, Stadler WM. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000;18:2419–26.
- Mertens WC, Eisnehauer EA, Moore M, et al. Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 1993;4:331–2.
- deMulder PH, Weissbach L, Jakse G, Osieka R, Blatter J. Gemcitabine: a phase II study in patient with advanced renal cancer. Cancer Chemother Pharmacol. 1996;37:491–5. CrossRef
- Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002;95:1629–36. CrossRef
- Neri B, Doni L, Fulignati C, et al. Gemcitabine plus epi-doxorubicin as first-line chemotherapy for bladder cancer in advanced or metastatic stage. Anticancer Res. 2002;22:2981–4.
- Milowsky MI, Rosmarin A, Tickoo SK, Papanicolaou N, Nanus DM. Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer. 2002;94:111–6. CrossRef
- Langner C, von Wasielewski R, Ratschek M, et al. Biological significance of p27 and Skp2 expression in renal cell carcinoma. a systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique. Virchows Arch. 2004;445:631–6. CrossRef
- Ishizaki H, Yano H, Tsuneoka M, et al. Overexpression of the mcy target gene Mina53 in advanced renal cell carcinoma. Pathol Int. 2007;57:672–80. CrossRef
- Visapaa H, Seligson D, Huang Y, et al. Ki67, gelsolin and PTEN expression in sarcomatoid renal tumors. Urol Res. 2003;30:387–9.
- Tickoo SK, Alden Olgac S, et al. Immunohistochemical expression of hypoxia inducible factor-1 alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol. 2007;177:1258–63. CrossRef
- Tamboli P, Prieto VG, Bekele BN, et al. The tyrosine kinase receptor c-Kit is overexpressed in sarcomatoid renal carcinomas. Proc Am Soc Clin Oncol. 2003;22:408a. (abst 1641).
- Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol. 2008;27:235–41. CrossRef
- Michaelson M, Schwarzberg A, Ryan D, McDermott D, Shapiro G, Tye L, Chen I, Selaru P, Wang E, Zhu A. a phase I study of sunitinib in combination with gemcitabine in advanced renal cell carcinoma and other solid tumors. Proc GU ASCO 2008. Abst 362. 2008.
- Michaelson D, McDermott DF, Atkins MB, Cho DC, Olivier KM, Schwarzberg AB, Choueiri TK: phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor risk metastatic renal cell carcinoma. Proc GU ASCO 2010. Abst 340. 2010.
- Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy
Volume 28, Issue 4 , pp 1530-1533
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Sarcomatoid renal cell cancer
- Industry Sectors